Data Insights

Atezolizumab by F. Hoffmann-La Roche for Ureter Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Ureter Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Ureter Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Anal Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Anal Cancer

Data Insights

Rituximab by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Marginal Zone B-cell Lymphoma

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Relapsed Acute Myeloid Leukemia

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Refractory Acute Myeloid Leukemia

Data Insights

Ranibizumab SR by F. Hoffmann-La Roche for Diabetic Macular Edema: Likelihood of Approval

Ranibizumab SR is under clinical development by F. Hoffmann-La Roche and currently in Pre-Registration for Diabetic Macular Edema. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ranibizumab SR in Diabetic Macular Edema

Data Insights

Ensomafusp alfa by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Ensomafusp alfa is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Marginal Zone B-cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Ensomafusp Alfa in Marginal Zone B-cell Lymphoma

Data Insights

Ensomafusp alfa by F. Hoffmann-La Roche for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Ensomafusp alfa is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Diffuse Large B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - Ensomafusp Alfa in Diffuse Large B-Cell Lymphoma

Data Insights

Forimtamig by F. Hoffmann-La Roche for Relapsed Multiple Myeloma: Likelihood of Approval

Forimtamig is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Forimtamig in Relapsed Multiple Myeloma

Data Insights

Forimtamig by F. Hoffmann-La Roche for Refractory Multiple Myeloma: Likelihood of Approval

Forimtamig is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Refractory Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Forimtamig in Refractory Multiple Myeloma

Data Insights

Ranibizumab SR by F. Hoffmann-La Roche for Diabetic Retinopathy: Likelihood of Approval

Ranibizumab SR is under clinical development by F. Hoffmann-La Roche and currently in Pre-Registration for Diabetic Retinopathy. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ranibizumab SR in Diabetic Retinopathy

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Satralizumab by F. Hoffmann-La Roche for Demyelinating Diseases: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases

Data Insights

Vemurafenib by F. Hoffmann-La Roche for Neuroblastoma: Likelihood of Approval

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Vemurafenib in Neuroblastoma

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Gastric Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastric Cancer

Data Insights

Vemurafenib by F. Hoffmann-La Roche for Thyroid Cancer: Likelihood of Approval

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thyroid Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Vemurafenib in Thyroid Cancer

Data Insights

Vemurafenib by F. Hoffmann-La Roche for Sarcomas: Likelihood of Approval

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Vemurafenib in Sarcomas

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Nephrotic Syndrome: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Nephrotic Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Nephrotic Syndrome

Data Insights

Tominersen by F. Hoffmann-La Roche for Huntington Disease: Likelihood of Approval

Tominersen is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Huntington Disease. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tominersen in Huntington Disease